PL2903608T3 - Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych - Google Patents
Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowychInfo
- Publication number
- PL2903608T3 PL2903608T3 PL13773230T PL13773230T PL2903608T3 PL 2903608 T3 PL2903608 T3 PL 2903608T3 PL 13773230 T PL13773230 T PL 13773230T PL 13773230 T PL13773230 T PL 13773230T PL 2903608 T3 PL2903608 T3 PL 2903608T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pharmaceutical composition
- propionic acid
- viral infections
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12187074 | 2012-10-03 | ||
| PCT/EP2013/070614 WO2014053592A1 (en) | 2012-10-03 | 2013-10-03 | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
| EP13773230.1A EP2903608B1 (en) | 2012-10-03 | 2013-10-03 | Pharmaceutical composition comprising propionic acid for use in the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2903608T3 true PL2903608T3 (pl) | 2019-12-31 |
Family
ID=47018852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13773230T PL2903608T3 (pl) | 2012-10-03 | 2013-10-03 | Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9415033B2 (pl) |
| EP (1) | EP2903608B1 (pl) |
| CA (1) | CA2886270C (pl) |
| ES (1) | ES2748632T3 (pl) |
| PL (1) | PL2903608T3 (pl) |
| WO (1) | WO2014053592A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220249485A1 (en) * | 2015-08-05 | 2022-08-11 | Cmpd Licensing, Llc | Topical compositions and methods of formulating the same |
| CA3020485A1 (en) * | 2016-05-17 | 2017-11-23 | Proponent Biotech Gmbh | Carboxylic acid for treating/preventing nasal congestion |
| EP3458042A1 (en) * | 2016-05-17 | 2019-03-27 | Proponent Biotech GmbH | Carboxylic acids for treating/preventing a skin disease |
| WO2018161039A1 (en) | 2017-03-03 | 2018-09-07 | Synovo Gmbh | Novel anti-infective and anti-inflammatory compounds |
| BR102019014081A8 (pt) * | 2019-07-08 | 2021-02-02 | Unicamp | compostos imunomoduladores e/ou seus sais farmaceuticamente aceitáveis, composição farmacêutica compreendendo compostos imunomoduladores e uso de compostos imunomoduladores na preparação de uma composição farmacêutica para tratamento de doenças virais |
| US20230263762A1 (en) * | 2020-07-02 | 2023-08-24 | Ecoplanet Environmental Llc | Composition and method for treating infections |
| WO2025257398A1 (en) * | 2024-06-14 | 2025-12-18 | Universite De Tours | Dicarboxylic acids and esters thereof for use in the treatment of a viral lung infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735967A (en) * | 1985-05-28 | 1988-04-05 | Neesby Torben E | Method for desensitizing the gastrointestinal tract from food allergies |
| KR100390480B1 (ko) | 1995-01-23 | 2003-10-04 | 디렉트-할러 아/에스 | 흡입기 |
| JP4543553B2 (ja) | 1999-03-03 | 2010-09-15 | オプティノーズ アズ | 鼻用の送り込み装置 |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| GB0420513D0 (en) | 2004-09-15 | 2004-10-20 | Optinose As | Powder delivery devices |
| GB0602980D0 (en) * | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
| GB0617191D0 (en) | 2006-08-31 | 2006-10-11 | York Pharma Plc | Improvements in pharmaceutical compositions |
| JP2008195713A (ja) | 2007-01-19 | 2008-08-28 | Shunkosha:Kk | 免疫調節剤 |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| PL2033635T3 (pl) | 2007-08-31 | 2012-01-31 | Sunny Pharmtech Inc | Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu |
| US20110077300A1 (en) | 2009-03-26 | 2011-03-31 | Jianping Ye | Metabolic Benefits to Butyrate as a Chronic Diet Supplement |
| WO2012131069A1 (en) | 2011-03-31 | 2012-10-04 | Proponent Biotech Gmbh | Short chain fatty acids and their derivatives for use in treatment immunogenic disorders |
-
2013
- 2013-10-03 ES ES13773230T patent/ES2748632T3/es active Active
- 2013-10-03 US US14/433,225 patent/US9415033B2/en active Active
- 2013-10-03 PL PL13773230T patent/PL2903608T3/pl unknown
- 2013-10-03 EP EP13773230.1A patent/EP2903608B1/en active Active
- 2013-10-03 WO PCT/EP2013/070614 patent/WO2014053592A1/en not_active Ceased
- 2013-10-03 CA CA2886270A patent/CA2886270C/en active Active
-
2016
- 2016-03-03 US US15/060,320 patent/US9884032B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9884032B2 (en) | 2018-02-06 |
| CA2886270C (en) | 2020-04-07 |
| US20150246015A1 (en) | 2015-09-03 |
| HK1210058A1 (en) | 2016-04-15 |
| US20160250168A1 (en) | 2016-09-01 |
| CA2886270A1 (en) | 2014-04-10 |
| WO2014053592A1 (en) | 2014-04-10 |
| EP2903608A1 (en) | 2015-08-12 |
| US9415033B2 (en) | 2016-08-16 |
| ES2748632T3 (es) | 2020-03-17 |
| EP2903608B1 (en) | 2019-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253225A0 (en) | Sulfamoyl-arylamides and their use as drugs to treat jaundice b | |
| LT2898885T (lt) | Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui | |
| IL232046A (en) | Furein derivatives for the treatment of viral infections | |
| IL236700A (en) | History of alkylpyrimidine for the treatment of viral infections and other diseases | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| IL235923A0 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof | |
| ZA201502238B (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| GB2515439B (en) | Vesicular formulations for use in the treatment of reduced mobility | |
| PL2903608T3 (pl) | Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych | |
| SMT201900282T1 (it) | Composizione farmaceutica per il trattamento delle infezioni da hiv | |
| GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
| ZA201501601B (en) | Virus purification and formulation process | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| SMT201700395T1 (it) | Composizioni farmaceutiche comprendenti acido ialuronico per il trattamento della patologia del black disc | |
| GB201208770D0 (en) | Compounds for use in the treatment of adenovirus infections | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |